Diurnal stock craters on PhIII fail; Ortho wins tentative FDA OK for Bryhali; Cavion insists failed PhII study was a win
→ Shares of the UK biotech Diurnal (AIM: $DNL) were pummeled today when the company reported that its Phase III study of Chronocort failed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
